CorMedix Inc. (FRA:19KA)
Germany · Delayed Price · Currency is EUR | Market Cap | 580.84M -20.0% |
| Revenue (ttm) | 346.97M +384.6% |
| Net Income | 156.13M +953.6% |
| EPS | 1.84 +651.9% |
| Shares Out | n/a |
| PE Ratio | 3.72 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 7.22 |
| Previous Close | 7.40 |
| Day's Range | 7.22 - 7.22 |
| 52-Week Range | 5.20 - 14.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New... [Read more]
News
CorMedix announces United States Court of Appeals affirms patent judgements
CorMedix (CRMD) announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the Northern District of Illinois that…
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of th...
CorMedix Transcript: Jefferies Global Healthcare Conference 2026
Management highlighted a transformation from a single-asset to a diversified institutional care company, driven by the Melinta acquisition and pipeline expansion. Key products REZZAYO and DefenCath are positioned for growth, with reimbursement and legislative changes as major catalysts. Guidance anticipates higher 2027 sales and continued business development.
CorMedix Slides: Corporate presentation
CorMedix has posted slides in relation to its latest quarterly earnings report, which was published on May 22, 2026.
CorMedix Transcript: RBC Capital Markets Global Healthcare Conference 2026
Preliminary REZZAYO data show efficacy and safety differentiation, with a broad FDA label sought and sNDA submission planned for H2. DefenCath guidance was raised on strong utilization, with 2027 revenue expected to rise as CMS reimbursement improves. Policy advocacy and pipeline expansion continue.
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Ca...
CorMedix Earnings Call Transcript: Q1 2026
Q1 2026 saw net revenue of $127.4M and adjusted EBITDA of $70M, driven by DefenCath and Melinta portfolio growth. Full-year guidance was raised for revenue and EBITDA, with DefenCath expected to see price changes post-reimbursement transition. REZZAYO's positive phase III results support an sNDA filing in H2 2026.
CorMedix Earnings release: Q1 2026
CorMedix released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
CorMedix Quarterly report: Q1 2026
CorMedix has published its Q1 2026 quarterly earnings report on May 14, 2026.
CorMedix reports Q1 EPS 43c, consensus 33c
Reports Q1 revenue $127.43M, consensus $104.96M. Joseph Todisco, CorMedix (CRMD) chairman and CEO, commented, “CorMedix has entered 2026 with strong momentum across all areas of our business. DefenCat...
CorMedix raises FY26 revenue view to $325M-$345M from $300M-$320M
Consensus $308.22M. Raises FY26 adjusted EBITDA view to $115M-$135M from $100M-$125M. The company said, “CorMedix (CRMD) updates previously established guidance for 2026 net revenue and adjusted EBITD...
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million ; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call ...
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the...
CorMedix Proxy statement: Proxy filing
CorMedix filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
CorMedix Proxy statement: Proxy filing
CorMedix filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Citizens healthcare analysts hold an analyst/industry conference call
Healthcare Analysts discuss expanding CorMedix (CRMD) Therapeutics’ Rezzayo for Prophylactic Use on an Analyst/Industry conference call to be held on April 30.
CorMedix price target raised to $14 from $13 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on CorMedix (CRMD) to $14 from $13 and keeps an Outperform rating on the shares. The company eported positive topline…
CorMedix announces ReSPECT clinical trial met primary endpoint
CorMedix (CRMD) announced Phase III topline results from the global ReSPECT clinical trial evaluating Rezzayo for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hemato...
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –
CorMedix Proxy statement: Proxy filing
CorMedix filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
CorMedix Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is expanding its institutional pharmaceutical portfolio following the Melinta acquisition, with REZZAYO's phase III prophylaxis data expected soon and DefenCath navigating a temporary reimbursement dip before a 2027 rebound. Pipeline growth includes a TPN indication, and financials remain strong with a $75M buyback program.
CorMedix to Participate in Needham Virtual Healthcare Conference
PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threateni...
CorMedix Transcript: The Citizens Life Sciences Conference 2026
REZZAYO's phase III prophylaxis data is expected later in Q2, targeting a $2B+ TAM in transplant patients. DefenCath's launch is strong, with Medicare Advantage seen as a major growth driver, and the Melinta acquisition has stabilized revenue. Operational scaling will follow key clinical milestones.
CorMedix Transcript: Leerink Global Healthcare Conference 2026
The company has evolved into a diversified specialty pharma, expanding its institutional care portfolio and advancing key assets like REZZAYO and DefenCath. Strong clinical results, strategic reimbursement efforts, and a robust financial position support growth, with multiple catalysts expected in the next 12–18 months.
CorMedix Slides: Corporate presentation
CorMedix has posted slides in relation to its latest quarterly earnings report, which was published on March 7, 2026.